Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.3K
Coagulation01:09

Coagulation

9.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RBC Transfusion Threshold Should Focus on Parameters of Tissue Oxygenation in Addition to Hemoglobin Concentration.

Chest·2025
Same author

Administration of fibrinogen concentrates to patients with severe bleeding. How much is enough?

Blood transfusion = Trasfusione del sangue·2025
Same author

Guided reversal of dabigatran in massive hemorrhagic shock.

Medicina intensiva·2024
Same author

Prospective assessment of platelet function in patients undergoing elective resection of glioblastoma multiforme.

Platelets·2023
Same author

A strategy to treat coagulopathy in patients with massive hemorrhage.

Medicina intensiva·2023
Same author

Whole Blood Platelet Aggregation Assessed by ROTEM Platelet Equipment in Healthy Volunteers from Southern Europe: A Verification Study.

The journal of applied laboratory medicine·2023

Related Experiment Video

Updated: Dec 20, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.9K

Current perspective on fibrinogen concentrate in critical bleeding.

Santiago R Leal-Noval1, Jose Fernández Pacheco2, Manuel Casado Méndez3

  • 1Neuro Critical Care Department, University Hospital "Virgen Del Rocío" and Institute of Biomedicine "IBIS" , 41013, Seville, Spain.

Expert Review of Clinical Pharmacology
|June 2, 2020
PubMed
Summary

Fibrinogen concentrate (FC) effectively treats severe hemorrhage in trauma and cardiac surgery. Early, goal-directed administration guided by specific tests is recommended, but preemptive use in non-bleeding patients is not advised.

Keywords:
Bleedinga5-FIBTEMcardiac surgerycoagulopathyfibrinogen concentratepostpartum hemorrhageratiorotemtraumatrauma-induced coagulopathy

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.1K
Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

9.6K

Related Experiment Videos

Last Updated: Dec 20, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.9K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.1K
Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

9.6K

Area of Science:

  • Critical Care Medicine
  • Hematology
  • Surgical Hemorrhage Management

Background:

  • Massive hemorrhage remains a significant, yet treatable, cause of mortality.
  • Current management strategies range from fixed ratio blood component therapy to goal-directed approaches using point-of-care testing and coagulation factor concentrates.

Purpose of the Study:

  • To review the current evidence and role of fibrinogen concentrate (FC) in managing massive hemorrhage.
  • To evaluate indications, dosage, and adverse effects, particularly thromboembolic events, associated with FC administration.

Main Methods:

  • Systematic review of guidelines, meta-analyses, randomized controlled trials, and observational studies.
  • Analysis focused on FC use in life-threatening hemorrhage, with or without coagulation testing.
  • Inclusion of studies assessing viscoelastic hemostatic assays and plasma fibrinogen levels for guidance.

Main Results:

  • Moderate to high-grade evidence supports FC use in severe hemorrhage associated with trauma and cardiac surgery.
  • Lower-grade evidence exists for postpartum hemorrhage and end-stage liver disease.
  • Preemptive administration in non-bleeding patients is not recommended.

Conclusions:

  • FC should be administered early and in a goal-directed manner, guided by specific viscoelastic parameters (A5- or A10-FIBTEM) or low fibrinogen levels.
  • Further research is needed on early FC use, its comparison to cryoprecipitate, and risks associated with high-dose administration.